RADIOSA

Highlights of the RADIOSA phase II trial presented at ESTRO24

European Society for Radiotherapy and Oncology (ESTRO) shared a paper on LinkedIn:

“Highlights of the RADIOSA phase II trial presented at ESTRO24: SBRT + short-term ADT significantly improves outcomes in oligorecurrent hormone-sensitive prostate cancer patients.

Report by Simon Spohn.”

Read further.
Source: ESTRO/LinkedIn

.

cancer ESTRO ESTRO24 hormone-sensitive prostate cancer OncoDaily Oncology prostate cancer prostate cancer patients RADIOSA trial radiotherapy Simon Spohn